Biogen’s Alzheimer’s Drug Candidate Gets FDA Review Extension
- Posted by ISPE Boston
- On February 11, 2021
Biogen and Eisai have announced that the FDA has extended the review period by three months for the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease. The new action date is June 7, 2021. If approved, aducanumab would be the first treatment to meaningfully change the course of the disease for […]
Read More